Amy D Wilson

US Patent:

7967929, Jun 28, 2011

Filed:

Dec 28, 2009

Appl. No.:

12/647707

Inventors:

Daniel Stec, III - Long Valley NJ, US
Amy Wilson - Blairstown NJ, US
Brian E. Fuchs - Hackettstown NJ, US
Neha Mehta - Succasunna NJ, US
Paula Cook - Succasunna NJ, US

Assignee:

The United States of America as represented by the Secretary of the Army - Washington DC

International Classification:

C06B 25/00
C06B 25/34
D03D 23/00
D03D 43/00

US Classification:

149 92, 149 88, 1491088, 1491094

Abstract:

Secondary crystalline high explosives are disclosed which are suitable for filling very small volume loading holes in micro-electric initiators for micro-electro-mechanical mechanisms (MEMS), used as safe and arm (S&A) devices. The explosives are prepared by adding the such a high explosive to an aqueous first volatile mobile phase, adding such a high explosive to a non-aqueous second volatile mobile phase, mixing the first and second volatile mobile phases and then loading the combined phases into the MEMS device and allowing the aqueous and non-aqueous solvents to evaporate depositing the high explosive. Enhanced adhesion between the deposited high explosive and enhanced rheological properties can be obtained by adding a polymeric binder to both mobile phases.

US Patent:

8161884, Apr 24, 2012

Filed:

Dec 29, 2010

Appl. No.:

12/980707

Inventors:

Victor Kokodis - Wharton NJ, US
George Sudol - Kenvil NJ, US
Brian Fuchs - Hackettstown NJ, US
Amy Wilson - Blairstown NJ, US

Assignee:

The United States of America as represented by the Secretary of the Army - Washington DC

International Classification:

F42B 12/22

US Classification:

102493, 102476, 102494, 102495, 102492, 89 53

Abstract:

A selective fragmentation pattern of explosive material is applied to a surface of a munition. None, some, or all of the explosive material in the selective fragmentation pattern may be detonated, selectively stamping the surface of the munition with the detonated explosive material. The portion of the selective fragmentation pattern selected for ignition is determined by lethality requirements of a target of the munition. Upon detonation of the munition, fragments are formed based on the selected portion of the selective fragmentation pattern. Consequently, igniting all, some, or none of the selective fragmentation pattern may vary lethality of a munition and one munition may be used for a wide range of lethality.

US Patent:

8636861, Jan 28, 2014

Filed:

Dec 29, 2010

Appl. No.:

12/980571

Inventors:

Daniel Stec, III - Long Valley NJ, US
Amy Wilson - Blairstown NJ, US
Brian E. Fuchs - Hackettstown NJ, US
Neha Mehta - Succasunna NJ, US
Paula Cook - Succasunna NJ, US

Assignee:

The United States of America as represented by the Secretary of the Army - Washington DC

International Classification:

C06B 25/34

US Classification:

149 92, 149 1992, 1491096

Abstract:

Secondary crystalline high explosives are disclosed which are suitable for filling very small volume loading holes in micro-electric initiators for micro-electro-mechanical mechanisms (MEMS), used as safe and arm (S&A) devices. The explosives are prepared by adding the such a high explosive to an aqueous first volatile mobile phase, adding such a high explosive to a non-aqueous second volatile mobile phase, mixing the first and second volatile mobile phases and then loading the combined phases into the MEMS device and allowing the aqueous and non-aqueous solvents to evaporate depositing the high explosive. Enhanced adhesion between the deposited high explosive and enhanced rheological properties can be obtained by adding a polymeric binder to both mobile phases.

US Patent:

20030077701, Apr 24, 2003

Filed:

Dec 20, 2001

Appl. No.:

10/029314

Inventors:

Carlos Forray - Paramus NJ, US
John Salon - Santa Paula CA, US
Thomas Laz - Parlin NJ, US
Raisa Nagorny - Fairlawn NY, US
Amy Wilson - Woodstock NY, US

International Classification:

C07K014/74
C07H021/04
C12P021/02
C12N005/06

US Classification:

435/069100, 435/320100, 435/325000, 530/350000, 536/023500

Abstract:

This invention provides an isolated nucleic acid encoding a human MCH1 receptor, a purified human MCH1 receptor, vectors comprising isolated nucleic acid encoding a human MCH1 receptor, cells comprising such vectors, antibodies directed to a human MCH1 receptor, nucleic acid probes useful for detecting nucleic acid encoding human MCH1 receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding human MCH1 receptors, transgenic, nonhuman animals which express DNA encoding a normal or mutant human MCH1 receptor, methods of isolating a human MCH1 receptor, methods of treating an abnormality that is linked to the activity of a human MCH1 receptor, as well as methods of determining binding of compounds to mammalian MCH1 receptors. This invention provides a method of modifying the feeding behavior of a subject which comprises administering to the subject an amount of an MCH1 antagonist effective to decrease the body mass of the subject and/or decrease the consumption of food by the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of an MCH1 antagonist effective to treat the subject's depression and/or anxiety.

US Patent:

20030130493, Jul 10, 2003

Filed:

Aug 26, 2002

Appl. No.:

10/228762

Inventors:

James Bonini - Oakland NJ, US
Ling Huang - Kearny NJ, US
Beth Borowsky - Flemington NJ, US
John Salon - Santa Paula CA, US
Amy Wilson - Woodstock NY, US
Raisa Nagorny - Fair Lawn NJ, US

International Classification:

C07H021/04
C12Q001/68
C07K014/705
C12P021/02
C12N005/06
A61K038/17

US Classification:

536/023500, 530/350000, 514/012000, 435/006000, 435/069100, 435/320100, 435/325000

Abstract:

This invention provides isolated nucleic acids encoding mammalian Edg7 receptors, purified mammalian Edg7 receptors, vectors comprising nucleic acid encoding mammalian Edg7 receptors, cells comprising such vectors, antibodies directed to mammalian Edg7 receptors, nucleic acid probes useful for detecting nucleic acid encoding mammalian Edg7 receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding mammalian Edg7 receptors, transgenic, nonhuman animals which express DNA encoding normal or mutant mammalian Edg7 receptors, methods of isolating mammalian Edg7 receptors, methods of treating an abnormality that is linked to the activity of the mammalian Edg7 receptors, as well as methods of determining binding of compounds to mammalian Edg7 receptors, methods of identifying agonists and antagonists of Edg7 receptors, and agonists and antagonists so identified.

US Patent:

20030143670, Jul 31, 2003

Filed:

Feb 20, 2002

Appl. No.:

10/080263

Inventors:

James Bonini - Oakland NJ, US
Amy Wilson - Woodstock NY, US

International Classification:

C12P021/02
C12N005/06
C07K014/705
C07H021/04

US Classification:

435/069100, 435/320100, 435/325000, 530/350000, 536/023500

Abstract:

This invention provides isolated nucleic acids encoding mammalian SNORF44 receptor, purified mammalian SNORF44 receptor, vectors comprising nucleic acid encoding mammalian SNORF44 receptor, cells comprising such vectors, antibodies directed to mammalian SNORF44 receptor, nucleic acid probes useful for detecting nucleic acid encoding mammalian SNORF44 receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding mammalian SNORF44 receptor, transgenic, nonhuman animals which express DNA encoding normal or mutant mammalian SNORF44 receptor, and methods of isolating mammalian SNORF44 receptor. This invention also provides methods of treating an abnormality that is linked to the activity of a mammalian SNORF44 receptor, as well as methods of determining binding of compounds to a mammalian SNORF44 receptor, methods of identifying agonists and antagonists of a SNORF44 receptor, and agonists and antagonists so identified.

US Patent:

62216139, Apr 24, 2001

Filed:

Dec 31, 1998

Appl. No.:

9/224426

Inventors:

John A. Salon - Montclair NJ
Thomas M. Laz - Parlin NJ
Raisa Nagorny - Fair Lawn NJ
Amy E. Wilson - New York NY

Assignee:

Synaptic Pharmaceutical Corporation - Paramus NJ

International Classification:

G01N 3353

US Classification:

435 71

Abstract:

This invention provides an isolated nucleic acid encoding a human MCH1 receptor, a purified human MCH1 receptor, vectors comprising isolated nucleic acid encoding a human MCH1 receptor, cells comprising such vectors, antibodies directed to a human MCH1 receptor, nucleic acid probes useful for detecting nucleic acid encoding human MCH1 receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding human MCH1 receptors, transgenic, nonhuman animals which express DNA encoding a normal or mutant human MCH1 receptor, methods of isolating a human MCH1 receptor, methods of treating an abnormality that is linked to the activity of a human MCH1 receptor, as well as methods of determining binding of compounds to mammalian MCH1 receptors.

US Patent:

62911953, Sep 18, 2001

Filed:

Jan 6, 2000

Appl. No.:

9/478602

Inventors:

John A. Salon - Montclair NJ
Thomas M. Laz - Parlin NJ
Raisa Nagorny - Fair Lawn NJ
Amy E. Wilson - New York NY

Assignee:

Synaptic Pharmaceutical Corporation - Paramus NJ

International Classification:

G01N 3353

US Classification:

435 721

Abstract:

This invention provides an isolated nucleic acid encoding a human MCH1 receptor, a purified human MCH1 receptor, vectors comprising isolated nucleic acid encoding a human MCH1 receptor, cells comprising such vectors, antibodies directed to a human MCH1 receptor, nucleic acid probes useful for detecting nucleic acid encoding human MCH1 receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding human MCH1 receptors, transgenic, nonhuman animals which express DNA encoding a normal or mutant human MCH1 receptor, methods of isolating a human MCH1 receptor, methods of treating an abnormality that is linked to the activity of a human MCH1 receptor, as well as methods of determining binding of compounds to mammalian MCH1 receptors.

Address:

6988 Andrews Rd, Memphis, TN 38135

VIN:

JTKDE177170165327

Make:

SCION

Model:

TC

Year:

2007